Fulgent Genetics マネジメント

マネジメント基準チェック /24

Fulgent Geneticsの CEO はMing Hsiehで、 May2016年に任命され、の在任期間は 8.5年です。の年間総報酬は$ 5.31Mで、 18.8%給与と81.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の28.8%を直接所有しており、その価値は€ 183.29M 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と3.8年です。

主要情報

Ming Hsieh

最高経営責任者

US$5.3m

報酬総額

CEO給与比率	18.8%
CEO在任期間	8.5yrs
CEOの所有権	28.8%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Fulgent Genetics の収益と比較して、Ming Hsieh の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$163m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$5m	US$1m	-US$168m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$5m	US$948k	US$143m
Sep 30 2022	n/a	n/a	US$272m
Jun 30 2022	n/a	n/a	US$392m
Mar 31 2022	n/a	n/a	US$461m
Dec 31 2021	US$6m	US$664k	US$507m
Sep 30 2021	n/a	n/a	US$569m
Jun 30 2021	n/a	n/a	US$493m
Mar 31 2021	n/a	n/a	US$417m
Dec 31 2020	US$248k	US$240k	US$214m
Sep 30 2020	n/a	n/a	US$48m
Jun 30 2020	n/a	n/a	US$3m
Mar 31 2020	n/a	n/a	-US$459k
Dec 31 2019	US$240k	US$240k	-US$411k
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$240k	US$240k	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$240k	US$240k	-US$3m

報酬と市場: Mingの総報酬 ($USD 5.31M ) は、 German市場 ($USD 1.42M ) の同規模の企業の平均を上回っています。

報酬と収益: Mingの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ming Hsieh (68 yo)

8.5yrs

在職期間

US$5,309,167

報酬

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.8% € 183.3m
Jian Xie	COO & President	6.6yrs	US$1.79m	1.43% € 9.1m
Paul Kim	Chief Financial Officer	8.8yrs	US$1.78m	0.40% € 2.6m
Hanlin Gao	Chief Scientific Officer & Laboratory Director	8.2yrs	US$1.49m	2.82% € 18.0m
Natalie Prescott	General Counsel & Chief Privacy Officer	2.5yrs	データなし	データなし
Doreen Ng	VP of Operations & Compliance and GM of Houston Office	4.1yrs	データなし	データなし
Jakub Sram	Vice President of Business Development & Sales	9.8yrs	データなし	データなし
Ellen Tsui	Vice President of Human Resources	2.5yrs	データなし	データなし
Brandon Perthuis	Chief Commercial Officer	4.7yrs	データなし	データなし
Lawrence Weiss	Chief Medical Officer	3.5yrs	データなし	データなし
Ray Yin	President & Chief Scientific Officer of Fulgent Pharma	2yrs	データなし	データなし

4.7yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: 7F0の経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.8% € 183.3m
Regina Groves	Independent Non-Employee Director	1.8yrs	US$625.60k	0.0039% € 24.9k
Linda Marsh	Independent Director	5.3yrs	US$270.50k	0.062% € 392.0k
Michael Nohaile	Independent Non-Employee Director	2.3yrs	US$268.50k	0.0079% € 50.0k

3.8yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 7F0の取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Fulgent Genetics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

COO & President recently sold €543k worth of stock

Chief Financial Officer recently sold €320k worth of stock

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Recent updates

New minor risk - Shareholder dilution

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

COO & President recently sold €543k worth of stock

New minor risk - Share price stability

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold €320k worth of stock

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.38 profit in 2Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Full year 2022 earnings released: EPS: US$4.77 (vs US$17.25 in FY 2021)

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.057 (vs US$4.13 in 3Q 2021)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold €94k worth of stock

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Chief Financial Officer recently sold €61k worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold €54k worth of stock

Chief Operating Officer recently sold €102k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Operating Officer recently sold €99k worth of stock

Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.

Investor sentiment improved over the past week

Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 3000E Index

Chief Financial Officer recently sold €75k worth of stock

マネジメント基準チェック /24